Literature DB >> 17259755

Performance characteristics of seven neuron-specific enolase assays.

Petr Stern1, Vladimir Bartos, Jana Uhrova, Drahomira Bezdickova, Zdislava Vanickova, Vojtech Tichy, Kveta Pelinkova, Richard Prusa, Tomas Zima.   

Abstract

BACKGROUND/AIMS: The determination of neuron-specific enolase (NSE) is relatively frequently requested in the differential diagnosis of small-cell lung carcinoma and non-small-cell lung carcinoma. The individual results of different immunoassays are often not comparable, which has been confirmed by long-term external quality assessments. In this study, we assessed the possible sources of these differences.
METHODS: More than 3,000 NSE analyses were performed using seven different immunoassays: DELFIA (PerkinElmer), Elecsys 2010 or Modular Analytics E 170 (Roche), Kryptor (B.R.A.H.M.S.), the enzyme-linked immunosorbent assay DRG and three assays based on immunoradiometric assays (DiaSorin, Immunotech and Schering-CIS). The following parameters were evaluated: precision profile of the individual methods, linearity on dilution and modified recovery, comparability and discrimination of immunoassays, sensitivity, and specificity.
RESULTS: There were differences in the correlation of values of certain low-concentration specimens. Some assays correlate well while others do not (up to fivefold difference), especially in the case of controls prepared synthetically. Therefore, the current non-standardized preparation of controls is questionable in our opinion. In the cutoff range, the difference in the results of native samples did not exceed its double value. The variation in values >100 microg/l obtained with different assays is <40%.
CONCLUSION: Our results confirmed expected matrix interferences especially in the range of normal and cutoff NSE concentrations. Another source of discrepancies can be attributed to different antibody affinity to alphagamma- and gammagamma-enolase isoenzymes. Finally, improper settings of cutoff values also contribute to the different discrimination of the methods. Copyright (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17259755     DOI: 10.1159/000098441

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  14 in total

1.  TD-12 workshop report: characterization of monoclonal antibodies to neuron-specific enolase.

Authors:  Elisabeth Paus; Klaus Hirzel; Maria Lidqvist; Matti Höyhtyä; David J Warren
Journal:  Tumour Biol       Date:  2011-05-14

2.  Serum neuron-specific enolase levels from the same patients differ between laboratories: assessment of a prospective post-cardiac arrest cohort.

Authors:  Michael Mlynash; Marion S Buckwalter; Ami Okada; Anna Finley Caulfield; Chitra Venkatasubramanian; Irina Eyngorn; Marcel M Verbeek; Christine A C Wijman
Journal:  Neurocrit Care       Date:  2013-10       Impact factor: 3.210

3.  Primary outcomes for resuscitation science studies: a consensus statement from the American Heart Association.

Authors:  Lance B Becker; Tom P Aufderheide; Romergryko G Geocadin; Clifton W Callaway; Ronald M Lazar; Michael W Donnino; Vinay M Nadkarni; Benjamin S Abella; Christophe Adrie; Robert A Berg; Raina M Merchant; Robert E O'Connor; David O Meltzer; Margo B Holm; William T Longstreth; Henry R Halperin
Journal:  Circulation       Date:  2011-10-03       Impact factor: 29.690

4.  Biomarkers of therapeutic efficacy in adolescents and adults with 5q spinal muscular atrophy: a systematic review.

Authors:  Maria Gavriilaki; Vasileios Papaliagkas; Alexandra Stamperna; Maria Moschou; Konstantinos Notas; Sotirios Papagiannopoulos; Marianthi Arnaoutoglou; Vasilios K Kimiskidis
Journal:  Acta Neurol Belg       Date:  2022-07-21       Impact factor: 2.471

5.  Serial soluble neurofilament heavy chain in plasma as a marker of brain injury after cardiac arrest.

Authors:  Malin Rundgren; Hans Friberg; Tobias Cronberg; Bertil Romner; Axel Petzold
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

6.  Serum neuron specific enolase - impact of storage and measuring method.

Authors:  Malin Rundgren; Tobias Cronberg; Hans Friberg; Anders Isaksson
Journal:  BMC Res Notes       Date:  2014-10-15

Review 7.  MicroRNAs: new biomarkers and therapeutic targets after cardiac arrest?

Authors:  Yvan Devaux; Pascal Stammet; Hans Friberg; Christian Hassager; Michael A Kuiper; Matt P Wise; Niklas Nielsen
Journal:  Crit Care       Date:  2015-02-11       Impact factor: 9.097

Review 8.  How to assess prognosis after cardiac arrest and therapeutic hypothermia.

Authors:  Fabio Taccone; Tobias Cronberg; Hans Friberg; David Greer; Janneke Horn; Mauro Oddo; Sabino Scolletta; Jean-Louis Vincent
Journal:  Crit Care       Date:  2014-01-14       Impact factor: 9.097

9.  Prognostication in comatose survivors of cardiac arrest: an advisory statement from the European Resuscitation Council and the European Society of Intensive Care Medicine.

Authors:  Claudio Sandroni; Alain Cariou; Fabio Cavallaro; Tobias Cronberg; Hans Friberg; Cornelia Hoedemaekers; Janneke Horn; Jerry P Nolan; Andrea O Rossetti; Jasmeet Soar
Journal:  Intensive Care Med       Date:  2014-11-15       Impact factor: 17.440

10.  Microdialysis Monitoring of CSF Parameters in Severe Traumatic Brain Injury Patients: A Novel Approach.

Authors:  Eric P Thelin; David W Nelson; Per Hamid Ghatan; Bo-Michael Bellander
Journal:  Front Neurol       Date:  2014-09-02       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.